MN-08

Small molecule

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Featured evidence outside this drug's tracked markets:NCT05660863 · Pulmonary Arterial Hypertension · Phase 1 · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Other / comorbidity
NCT05660863 · Guangzhou Magpie Pharmaceuticals Co., Ltd.
2027-09-01 – 2028-06-01 · Pulmonary Arterial Hypertension
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow MN-08 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
March 2028 (1)
Phase 1Pulmonary Arterial HypertensionNot yet recruiting
Est. primary completion 2028-03-30 · NCT05660863 · CT.gov ↗
What to watch

See the full readout calendar ↗